The study of sodium-glucose cotransporter-2 inhibitors for Epilepsy treatment
The company Washington University School of Medicine is commencing recruitment for the clinical trial of the Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy.
The trial officially began on the August 17, 2022 and is planned to complete on June 30, 2023.
About 30% of persons with epilepsy have seizures that do not respond to drugs. The ketogenic diet is an effective treatment option for them, but this high fat diet is strict and difficult to maintain. The properties of gliflozins, which often are used to treat type 2 diabetes, make them a potential replacement for the ketogenic diet. This pilot study will determine whether gliflozins induce ketosis and could be used to treat adults with epilepsy safely.
The link to the complete study profile:
